Is it safe?
Can CAI take a bad year?
Caris Life Sciences, Inc. carries $291M of net debt at 1.67× EBITDA: a load its earnings can carry.
$291M
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 1.67×
Net debt / EBITDA
- Altman Z-score
- 4.40
Altman Z-score · safe zone, above 3
- Interest cover
- 3.27×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $393M
- Cash and short-term investments
- $102M
- Net debt
- $291M
- EBITDA, trailing twelve months
- $174M
- Operating profit, trailing twelve months
- $153M
- Debt / equity
- 0.66×
- Total debt / EBITDA
- 2.26×
- Annualised volatilitytwo years of daily moves
- 66%
- Worst drawdown on file
- −63%
- Below its 52-week high
- −32%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.